Sugi Predict

Sugi Predict / Compounds / SCHEMBL7921087

SCHEMBL7921087

SCHEMBL7921087

Cc1ccc2nc(C)nn2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 2/20 0.46
▸ RAB9A P51151 7/20 0.41
▸ NPC1 O15118 7/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ PAX8 Q06710 2/20 0.41
▸ MITF O75030 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KDM5A P29375 1/20 0.41
▸ KDM5C P41229 1/20 0.41
▸ DYRK1A Q13627 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.38
▸ TP53 P04637 3/20 0.38
▸ PKM P14618 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CDK5 Q00535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27037441 0.79 AHR (0.44) AHRRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL10271997 0.79 AHR (0.51) AHRRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL618586 0.79 AHR (0.60) AHRRAB9ANPC1PAX8DYRK1A
SCHEMBL5930721 0.79 DYRK1A (0.38) AHRDYRK1AAPPCOMTTGFBR1
SCHEMBL22438963 0.79 DYRK1A (0.38) AHRRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL12779142 0.79 DYRK1A (0.38) AHRDYRK1ACOMTTGFBR1TLR9
SCHEMBL10044580 0.79 PIK3CG (0.44) AHRRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL19295932 0.79 AHR (0.44) AHRRAB9ANPC1SMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL31600019 0.78 DYRK1A (0.37) AHRRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL15294468 0.76 DYRK1A (0.36) AHRRAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137329-A1 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2024-06-27 — — WO disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 — — US disclosed
WO-2023114200-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 — — WO disclosed
WO-2023114198-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 — — WO disclosed
WO-2023098880-A1 FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2023-06-08 — — WO disclosed
US-20230167068-A1 BENZOPYRAZOLE COMPOUND MEDSHINE DISCOVERY INC. (CN) 2023-06-01 — — US disclosed
US-20230167068-A1 BENZOPYRAZOLE COMPOUND MEDSHINE DISCOVERY INC. (CN) 2023-06-01 — — US disclosed
US-20230159520-A1 TYK-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 — — US disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 — — EP disclosed
WO-2011081173-A1 TETRACYCLIC COMPOUND 協和発酵キリン株式会社 (JP) 2011-07-07 — — WO disclosed
US-20110098471-A1 OXAZOLIDINONE DERIVATIVE HAVING FUSED RING RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-04-28 — — US disclosed
WO-2010065668-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2010-06-10 — — WO disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed
US-20080287434-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-20 — — US disclosed
US-20080287434-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-20 — — US disclosed
WO-2007034252-A1 AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS SANOFI-AVENTIS (FR) 2007-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR AHR 4090/4885RAB9A 1430/4885NPC1 1106/4885
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH AHR 3181/4885RAB9A 2435/4885NPC1 245/4885
US-20230167068-A1 BENZOPYRAZOLE COMPOUND ABCB1, CYP3A43, CYP3A5 AHR 1184/4885RAB9A 1260/4885NPC1 237/4885
US-20110098471-A1 OXAZOLIDINONE DERIVATIVE HAVING FUSED RING OXER1, ALOX12, CYP1A1 AHR 20/4885RAB9A 3457/4885NPC1 1177/4885
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB AHR 251/4885RAB9A 3890/4885NPC1 1126/4885
US-20080287434-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands CCR3, CCR1, CCR4 AHR 465/4885RAB9A 1905/4885NPC1 468/4885
US-20230159520-A1 TYK-2 INHIBITOR TYK2, IRAK2, PTK2B AHR 802/4885RAB9A 3713/4885NPC1 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.